AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to ...

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments ...

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology PR Newswire NORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 ...